Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | THRA | P10827 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26905254 | 0.81 | NPC1 (0.49) | NPC1RAB9AMAPTSMN1; SMN2L3MBTL1 | |
| SCHEMBL6627314 | 0.79 | NPC1 (0.48) | NPC1RAB9AMAPTSMN1; SMN2L3MBTL1 | |
| SCHEMBL9749185 | 0.74 | CDC25B (0.48) | NPC1RAB9AMAPTL3MBTL1 | |
| SCHEMBL3295010 | 0.74 | NPC1 (0.47) | NPC1RAB9AMAPTSMN1; SMN2L3MBTL1 | |
| SCHEMBL5113336 | 0.74 | NPC1 (0.43) | NPC1RAB9AMAPTSMN1; SMN2L3MBTL1 | |
| SCHEMBL5113606 | 0.74 | TDP1 (0.53) | NPC1RAB9AMAPTSMN1; SMN2L3MBTL1 | |
| SCHEMBL12772159 | 0.74 | MAOB (0.45) | MAPTSMN1; SMN2L3MBTL1THRATHRB | |
| SCHEMBL29097577 | 0.74 | RAB9A (0.49) | NPC1RAB9AMAPTSMN1; SMN2L3MBTL1 | |
| SCHEMBL9748801 | 0.73 | LTA4H (0.50) | NPC1RAB9AMAPTSMN1; SMN2L3MBTL1 | |
| SCHEMBL8859833 | 0.72 | NPC1 (0.62) | NPC1RAB9AMAPTSMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0201071-B1 | 2-SUBSTITUTED-1-NAPHTHOLS AS 5-LIPOXYGENASE INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-03-04 | — | — | EP | disclosed |
| US-5026759-A | Antiinflammatory agents respiratory system disorders | DU PONT MERCK PHARMACEUTICAL (US) | 1991-06-25 | — | — | US | disclosed |
| US-4985442-A | ANTIINFLAMMATORY, LUNG DISEASES, PSORIASIS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-01-15 | — | — | US | disclosed |
| US-4985435-A | TREATMENT OF INFLAMMATION, OBSTRUCTIVE LUNG DISEASES AND PSORIASIS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-01-15 | — | — | US | disclosed |
| US-4906636-A | 2-Substituted-1-naphthols as 5-lipoxygenase inhibitors | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-03-06 | — | — | US | disclosed |
| US-4833164-A | ANTIINFLAMMATORY AGENTS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-05-23 | — | — | US | disclosed |
| EP-0201071-A2 | 2-Substituted-1-naphthols as 5-lipoxygenase inhibitors | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1986-11-12 | — | — | EP | disclosed |